🆕🔥Breaking clinical trials at #KidneyWk

Promising drugs for future in Nephro😎

✅Sparsentan-FSGS(DUPLEX)

✅Bardoxolone-DKD(AYAME)

✅CKD-Zibotentan(ET 1 antagonist) ZENITH

✅CKD-Aldosterone synthase inhibitor

✅IgA Nephropathy-Sibeprenlimab- Monoclonal Ab against APRIL

Sibeprenlimab in IgA Neph 🔥🔥🆕

🧬Sibeprenlimab-humanised monoclonal IgG2 Ab-Blocks APRIL

⬇️galactose-deficient IgA1

📇 12 months i.v sibeprenlimab in Bx confirmed IgA Neph significantly greater ⬇️ in proteinuria than placebo

NEJM

#MyOtsuka - Sibeprenlimab Receives Historic Breakthrough Designation by FDA bit.ly/3T46Nuj

#MyOtsuka - Sibeprenlimab Receives Historic Breakthrough Designation by FDA bit.ly/3UMgHSz

#MyOtsuka - Sibeprenlimab Receives Historic Breakthrough Designation by FDA bit.ly/3SFX3VJ

🔥Springtime for IgA Nephropathy with APRIL

🌼APRIL inhibition in IgAN

✅Sibeprenlimab-Monoclonal antibody against APRIL (A proliferation ligand)

✅Phase 2 trial in IgAN highly impressive- Significant reduction in proteinuria with sibeprenlimab

NEJM

#APRIL is a protein that likely plays a key role in the formation of IgA. Pts w higher levels of APRIL may produce higher levels of abnormal IgA. #Sibeprenlimab -monoclonal antibody to block the activity of APRIL. #visionary trial. Now enrolling globally. #NephTwitter #IgAN #NKF

大塚製薬のsibeprenlimabが、IgA腎症の治療薬として米国FDAからブレークスルーセラピー指定を受領👏

このヒト化モノクローナル抗体は、IgA腎症の進行に重要な役割を果たすB細胞成長因子、サイトカインAPRILの作用を阻害します。

Phase 2

大塚製薬は今一番ノリに乗ってる企業.グローバル4製品の増収に加えエビリファイ2ヶ月製剤,レキサルティADアジテーション効能追加,大鵬のフチバチニブ承認等安定感抜群.次のブロックバスター候補はIgA腎症のsibeprenlimabだがノバルティスやVeraのatacicept等競合多くHIF-PH薬時のように乗り遅れると…

💥NEJM @nejm update: A Phase 2 Trial of Sibeprenlimab in Pts with IgAN

⚡️🗓12 months of Rx with sibeprenlimab resulted in a significantly greater ⬇️ proteinuria than placebo

nejm.org/doi/full/10.10….

En nefropatía por IgA proteinurica, Sibeprenlimab (anticuerpo monoclonal que inactiva APRIL) de aplicación IV mensual, comparado placebo, ↓62% proteinuria, estabiliza TFGe, 26% alcanzó remisión clínica y fue seguro

Ensayo clínico ENVISION

NEJM 2023
DOI: 10.1056/NEJMoa2305635

En nefropatía por IgA de alto riesgo de progresión, sibeprenlimab (anticuerpo monoclonal que neutraliza APRIL) de aplicación mensual durante un año, ↓62% proteinuria y evitó perder ~6ml/min de TFGe, además fue muy seguro.

Ensayo clínico ENVISION

NEJM
DOI: 10.1056/NEJMoa2305635

IgA nefropatisi diğer glomerülonefritlerin aksine immünsupresif ilaçlara dirençli. Ve dünyada en sık görülen glomerülonefrit. O nedenle çok önemli bir çalışma..
tinyurl.com/mr2dtsb4
Bir Faz 2 Çalışması: Sibeprenlimab IgA Nefropatili hastalarda proteinüriyi düşürüyor.

At the #ISNCON23 Mohit Mathur first author of 'A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy' in the NEJM presents data from that trial. Most pts were recruited for the trial from India.
nejm.org/doi/10.1056/NE…

En pacientes con nefropatía por IgA, 12 meses de tratamiento con SIBEPRENLIMAB dieron como resultado una disminución significativamente mayor de la proteinuria, comparado con placebo.

N Engl J Med 2024;390:20-31.

Pick 3 goes to Joshua Waitzman, MD PhD wild card pick ♥️♦️♠️♣️
Poster session: phase 2 to trial for Sibeprenlimab #NephJC

nejm.org/doi/pdf/10.105…

An LBCT poster in the @nejm

Sibeprenlimab in IgA Nephropathy
Phase 2
Reduces proteinuria

#KidneyWk
H/t Cristina Popa
nejm.org/doi/full/10.10…

Sibeprenlimab gets FDA Breakthrough Therapy tag for Immunoglobulin A Nephropathy therapy.

More Info: pryzm.ozmosi.com/product/20777 $XBI $IBB $XPH $PPH

En este estudio clínico aleatorizado fase 2 de pacientes con nefropatía por IgA, 12 meses de tratamiento con SIBEPRENLIMAB dieron como resultado una disminución significativamente mayor de la proteinuria, comparado con placebo.

N Engl J Med 2023; DOI: 10.1056/NEJMoa2305635

Complete results of a positive Phase 2 trial on Sibeprenlimab's effectiveness in treating Immunoglobulin A Nephropathy (IgAN) published in New England Journal of Medicine.

More Info: pryzm.ozmosi.com/product/20777 $XBI $IBB $XPH $PPH